Medical technology group, headquartered in Dublin, Medtronic is launching its new pivotal trial for its upgraded and next-generation Guardian ™ continuous glucose monitoring sensor to assist patients with type 1 and 2 diabetes.
The new technology will be designed to improve general system performance, boost accuracy, and reduce sensor calibrations.
Trials will study the sensor over the course of seven days in up to 460 participants with type 1 or 2 diabetes between the ages of two and 80 years old.
User experience will be the key focus for the length of the trial, during which time participants will be randomly assigned to sensor wear testing days and times and locations.
Vice president of research and development for the Diabetes Group at Medtronic, Ali Dianaty, commented: “We are very excited about this next-generation CGM sensor as it is designed to require calibrations only on the first day of wear, reducing fingersticks by 95 per cent over our current CGM.
"We strongly believe calibration on the first day of wear is necessary to improve day one performance, which we know from physician and patient feedback is a challenge for all sensors. Our research shows this day one performance is critical for keeping patients safe in hybrid closed loop, or Auto Mode, which we know from real-world experience delivers the optimal Time in Range for patients on insulin therapy."
Medtronic’s trials will boost the company’s contributions to the medical technology market and will support growth and expansion in the medical professional field.